Nuance Investments LLC Takes Position in Danaher Corporation $DHR

Key Points

• Nuance Investments acquired 17,162 Danaher shares in the second quarter, valued at approximately $3.27 million. Institutional investors and hedge funds collectively own 79.05% of the company.
• Analysts maintain a generally positive outlook, with Danaher receiving a consensus “Moderate Buy” rating and an average price target of $228.91, despite several recent target-price reductions.
• Danaher exceeded quarterly expectations, reporting $1.94 in EPS versus the $1.85 consensus and $6.26 billion in revenue, up 5.5% year over year.

Nuance Investments LLC acquired a new stake in Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 17,162 shares of the conglomerate's stock, valued at approximately $3,269,000.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in Danaher in the second quarter valued at approximately $10,492,520,000. Norges Bank bought a new stake in shares of Danaher during the fourth quarter worth $2,177,106,000. Bank of New York Mellon Corp acquired a new stake in shares of Danaher during the second quarter worth $712,875,000. Viking Global Investors LP raised its holdings in shares of Danaher by 543.9% during the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate's stock worth $574,351,000 after acquiring an additional 2,455,994 shares during the period. Finally, Deutsche Bank AG bought a new stake in Danaher in the 2nd quarter valued at $446,265,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DHR. Wells Fargo & Company reduced their target price on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 22nd. TD Cowen cut their price target on Danaher from $240.00 to $236.00 and set a "buy" rating on the stock in a report on Wednesday, July 22nd. Evercore reaffirmed an "outperform" rating and set a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. Jefferies Financial Group reiterated a "buy" rating and set a $245.00 price objective on shares of Danaher in a report on Tuesday, April 21st. Finally, UBS Group dropped their target price on Danaher from $270.00 to $250.00 and set a "buy" rating on the stock in a research report on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $228.91.

Danaher Trading Down 0.0%

Shares of NYSE:DHR opened at $202.44 on Tuesday. The company's 50-day moving average price is $193.52 and its two-hundred day moving average price is $192.67. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock has a market capitalization of $142.31 billion, a PE ratio of 35.96, a price-to-earnings-growth ratio of 2.52 and a beta of 0.78.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analysts' expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.Danaher's revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.77 EPS. On average, equities analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source